semaglutide in Chinese subjects with T2D have been demonstrated in a phase 3a clinical trial (SUSTAIN CHINA MRCT, ClinicalTrials.gov identifier: NCT03061214)
When Sarah stepped on the scale three months after starting GLP-1s, she felt an incredible rush of accomplishment
There are also a few cautions the FDA notes specific to this drug, including but not limited to: risk of pancreatitis hypoglycemia (low blood sugar) when used in conjunction with certain other drugs renal impairment or kidney failure acute gallbladder disease increased risk of thyroid C-cell tumors The FDA notes that patients who have had, or have family members who have had, medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use liraglutide, nor should individuals who have experienced prior serious hypersensitivity reaction to the drug
The Science of Safety: Adverse Effects of GLP-1 Receptor Agonists as Glucose-Lowering and Obesity Medications
Harvard Health Publishing
Thats why medical weight loss, including the use of GLP-1 medications, is an increasingly important option